Metastat RGCC is an advanced test to detect specific blood-borne markers that can accurately determine whether a secondary cancerous tumour is likely to develop and its potential location.
During the test, we analyse a sample of a patient’s blood in our state-of-the-art laboratory to analyse, identify and measure circulating tumour cells (CTCs).
Metastat RGCC is suitable for all patients who have received a confirmed cancer diagnosis. The test can accurately detect the development of secondary cancers or tumours and improve personalised cancer treatments.
Test details
Sample type
Whole peripheral blood sample
Analysis period
Approx. 7 days
Cancer type
Applicable for all cancer types
Final results
10-12 days after sample delivery
Sample size
10-15 ml peripheral whole blood
Price*
825 €
* The prices of the tests may be an issue of local additional taxes and value added taxes which are dependent of each country’s legislation. The prices may vary in areas that are under the jurisdiction of a distributor. These prices are for the tests only, and they do not include in-office fees such as consultation, blood draws, etc.
* RGCC is not liable for any third-party comments or claims regarding our products. For accurate and up-to-date information about our offerings, please refer to our official website: rgcc-international.com
